AU699914B2 - Novel enzyme inhibitors, their synthesis, and methods for use - Google Patents

Novel enzyme inhibitors, their synthesis, and methods for use Download PDF

Info

Publication number
AU699914B2
AU699914B2 AU78476/94A AU7847694A AU699914B2 AU 699914 B2 AU699914 B2 AU 699914B2 AU 78476/94 A AU78476/94 A AU 78476/94A AU 7847694 A AU7847694 A AU 7847694A AU 699914 B2 AU699914 B2 AU 699914B2
Authority
AU
Australia
Prior art keywords
pyrimidine
compound
phenylthio
uracil
phenylselenenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU78476/94A
Other languages
English (en)
Other versions
AU7847694A (en
Inventor
Mahmoud H El Kouni
Fardos N. M. Naguib
Raymond F. Schinazi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FARDOS N M NAGUIB
Original Assignee
FARDOS N M NAGUIB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FARDOS N M NAGUIB filed Critical FARDOS N M NAGUIB
Publication of AU7847694A publication Critical patent/AU7847694A/en
Application granted granted Critical
Publication of AU699914B2 publication Critical patent/AU699914B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU78476/94A 1993-11-02 1994-09-30 Novel enzyme inhibitors, their synthesis, and methods for use Ceased AU699914B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/146838 1993-11-02
US08/146,838 US5476855A (en) 1993-11-02 1993-11-02 Enzyme inhibitors, their synthesis and methods for use
PCT/US1994/011173 WO1995012400A1 (en) 1993-11-02 1994-09-30 Novel enzyme inhibitors, their synthesis, and methods for use

Publications (2)

Publication Number Publication Date
AU7847694A AU7847694A (en) 1995-05-23
AU699914B2 true AU699914B2 (en) 1998-12-17

Family

ID=22519188

Family Applications (1)

Application Number Title Priority Date Filing Date
AU78476/94A Ceased AU699914B2 (en) 1993-11-02 1994-09-30 Novel enzyme inhibitors, their synthesis, and methods for use

Country Status (9)

Country Link
US (3) US5476855A (enExample)
EP (1) EP0725641B1 (enExample)
JP (1) JP3621102B2 (enExample)
AT (1) ATE198046T1 (enExample)
AU (1) AU699914B2 (enExample)
DE (1) DE69426423T2 (enExample)
ES (1) ES2155093T3 (enExample)
PT (1) PT725641E (enExample)
WO (1) WO1995012400A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476855A (en) * 1993-11-02 1995-12-19 Mahmoud H. el Kouni Enzyme inhibitors, their synthesis and methods for use
EP0748316B1 (en) * 1994-02-28 2002-05-08 Sunkyong Industries Co., Ltd. Pyrimidine acyclonucleoside derivatives
US5811073A (en) * 1995-06-19 1998-09-22 President And Fellows Of Harvard College Method for radioisotopic detection and localization of inflammation in a host
US5719132A (en) * 1996-06-27 1998-02-17 Bristol-Myers Squibb Company Compositions and methods of treating HIV with d4T, 5-fluorouracil/tegafur, and uracil
US6306909B1 (en) 1997-03-12 2001-10-23 Queen's University At Kingston Anti-epileptogenic agents
US6177437B1 (en) * 1998-09-04 2001-01-23 University Of Massachusetts Medical Center Inhibitors of Herpes Simplex virus uracil-DNA glycosylase
US6608197B2 (en) * 2000-01-25 2003-08-19 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
US7501429B2 (en) * 2001-04-11 2009-03-10 Queen's University At Kingston Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
CA2448160A1 (en) * 2001-05-25 2002-12-05 Queen's University At Kingston Heterocyclic beta-amino acids and their use as anti-epileptogenic agents
EP1655301B1 (en) * 2003-08-04 2015-03-11 Valery Khazhmuratovich Zhilov Cyclic bioisosters of purine system derivatives and a pharmaceutical composition based thereon
CN102441170A (zh) * 2004-12-03 2012-05-09 阿迪赫里克斯技术公司 与5-fu和5-fu前药组合施用dpd抑制剂的方法
US20100158966A1 (en) * 2005-05-24 2010-06-24 Ted Reid Selenium-based biocidal formulations and methods of use thereof
EP1898706B1 (en) * 2005-05-24 2018-04-04 Selenium, Ltd. Selenium-based biocidal formulations and methods of use thereof
US9370187B2 (en) 2005-05-24 2016-06-21 Selenium, Ltd. Selenium-based biocidal formulations and methods of use thereof
US8236337B2 (en) * 2005-05-24 2012-08-07 Selenium, Ltd. Anti-microbial orthodontic compositions and appliances and methods of production and use thereof
US20100158967A1 (en) * 2005-05-24 2010-06-24 Ted Reid Selenium-based biocidal formulations and methods of use thereof
KR101452518B1 (ko) * 2005-08-22 2014-10-21 멜리어 파마슈티칼스 아이, 인코포레이티드 Ｌｙｎ 키나제 활성의 조절 및 관련된 장애의 치료를 위한방법 및 제제
EP2120581A4 (en) * 2007-02-20 2011-03-16 Melior Pharmaceuticals I Inc METHODS OF IDENTIFYING LYN KINASE ACTIVATORS
EP2180894A4 (en) * 2007-07-23 2012-08-29 Melior Pharmaceuticals I Inc METHOD OF ACTIVATING IRS-1 AND ACT
WO2009114325A2 (en) 2008-03-03 2009-09-17 Tosk, Incorporated Methotrexate adjuvants to reduce toxicity and methods for using the same
US8552184B2 (en) * 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism
EP2488182B1 (en) * 2009-10-14 2017-07-19 Elion Oncology LLC Treating neurotoxicity associated with combinations of 5-FU or its prodrugs and DPD inhibitors
WO2011150300A1 (en) 2010-05-28 2011-12-01 Melior Pharmaceuticals I, Inc. Prevention of pancreatic beta cell degeneration
EP3609500B1 (en) 2017-04-10 2024-11-13 Melior Pharmaceuticals I, Inc. Treatment of adipocytes
US11446303B2 (en) 2019-06-21 2022-09-20 Tosk, Inc. Uridine phosphorylase (UPase) inhibitors for treatment of liver conditions
WO2025260023A1 (en) * 2024-06-14 2025-12-18 Spiral Therapeutics, Inc. Methods of treating otic disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4613604A (en) * 1985-07-31 1986-09-23 Brown University Research Foundation Hydroxymethyl derivatives of 5-benzylacyclouridine and 5-benzoyloxybenzylacyclouridine and their use as potentiators for 5-fluoro-2'-deoxyuridine
US5077280A (en) * 1988-04-12 1991-12-31 Brown University Research Foundation Treatment of viral infections

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755295A (en) * 1969-10-24 1973-08-28 Syntex Corp 1-(2-amino-2-deoxy-{62 -d-ribofuranosyl) pyrimidines and derivatives thereof
US3687931A (en) * 1970-03-19 1972-08-29 Syntex Corp Halogenated purine and pyrimidine nucleosides and process therefor
JPS5738774A (en) * 1980-08-19 1982-03-03 Chugai Pharmaceut Co Ltd Uracil derivative and its preparation
US4868187A (en) * 1980-09-16 1989-09-19 Syntex (U.S.A.) Inc. Anti-viral N-substituted pyrimidines
CH676712A5 (enExample) * 1988-03-31 1991-02-28 Mitsubishi Chem Ind
DE69126469T2 (de) * 1990-03-29 1998-01-29 Mitsubishi Chem Corp Pyrimidin-Nukleosid-Derivate und antivirale Mittel, die diese Derivate als aktiven Bestandteil enthalten
US5141943A (en) * 1990-04-12 1992-08-25 Brown University Research Foundation 5-benzyl barbiturate derivatives
US5476855A (en) * 1993-11-02 1995-12-19 Mahmoud H. el Kouni Enzyme inhibitors, their synthesis and methods for use
KR0151811B1 (ko) * 1993-12-21 1998-10-15 강박광 신규한 항바이러스성 2,4-피리미딘디온 유도체 및 그의 제조방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4613604A (en) * 1985-07-31 1986-09-23 Brown University Research Foundation Hydroxymethyl derivatives of 5-benzylacyclouridine and 5-benzoyloxybenzylacyclouridine and their use as potentiators for 5-fluoro-2'-deoxyuridine
US5077280A (en) * 1988-04-12 1991-12-31 Brown University Research Foundation Treatment of viral infections

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PHARMAC. THERAP. V8 1981 P629-651 *

Also Published As

Publication number Publication date
EP0725641A4 (enExample) 1996-09-04
US5476855A (en) 1995-12-19
JP3621102B2 (ja) 2005-02-16
EP0725641A1 (en) 1996-08-14
JPH09507054A (ja) 1997-07-15
AU7847694A (en) 1995-05-23
ES2155093T3 (es) 2001-05-01
WO1995012400A1 (en) 1995-05-11
EP0725641B1 (en) 2000-12-13
DE69426423T2 (de) 2001-07-12
US5721241A (en) 1998-02-24
ATE198046T1 (de) 2000-12-15
USRE37623E1 (en) 2002-04-02
PT725641E (pt) 2001-05-31
DE69426423D1 (de) 2001-01-18

Similar Documents

Publication Publication Date Title
EP0725641B1 (en) NOVEL INHIBITORS OF URIDINE PHOSPHORYLASE (UrdPase) AND DIHYDROURACIL DEHYDROGENASE (DHUDase)
US5141943A (en) 5-benzyl barbiturate derivatives
Tanaka et al. Synthesis and antiviral activity of deoxy analogs of 1-[(2-hydroxyethoxy) methyl]-6-(phenylthio) thymine (HEPT) as potent and selective anti-HIV-1 agents
Niedzwicki et al. 5-Benzylacyclouridine and 5-benzyloxybenzylacyclouridine, potent inhibitors of uridine phosphorylase
US5627160A (en) L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
JP4737934B2 (ja) ヌクレオシドホスホリラーゼ及びヌクレオシダーゼのインヒビター
US6436945B2 (en) Substituted O6-benzyl-8-aza-guanines
Rosowsky et al. Synthesis and antitumor activity of an acyclonucleoside derivative of 5-fluorouracil
Goudgaon et al. Phenylselenenyl-and phenylthio-substituted pyrimidines as inhibitors of dihydrouracil dehydrogenase and uridine phosphorylase
JPH06507902A (ja) 肝臓で代謝される薬物前駆物の決定とその治療的利用
CN112110938B (zh) 一种作为蛋白质激酶抑制剂的化合物及其制备方法和用途
JPS63297381A (ja) ９−〔２−（ヒドロキシメチル）シクロアルキルメチル〕グアニン類
CA2039039C (en) Pyrimidine nucleoside derivative and antiviral agent containing the derivative as active ingredient
CZ16196A3 (en) 5-substituted or 5,6-dihydro-5-substituted uracil derivative or a pharmaceutical preparation or a combination thereof containing said derivative
Siddiqui et al. Chemistry and anti-HIV properties of 2'-fluoro-2', 3'-dideoxyarabinofuranosylpyrimidines
EP0711555A2 (en) Enzyme inactivators
CA2176720C (en) Novel enzyme inhibitors, their synthesis, and methods for use
JPS63287770A (ja) １−〔２−（ヒドロキシメチル）シクロアルキルメチル〕−５−置換ウラシル類
JP2000516578A (ja) アデノシンデアミナーゼ阻害剤
KR100368891B1 (ko) 신규한 항바이러스성 2,4-피리미딘디온 유도체
Schinazi et al. Synthesis, antiviral activity, cytotoxicity, and cellular pharmacology of 5-carboranyl-pyrimidine nucleosides
US6677345B1 (en) Cyclin dependent kinase inhibitors
JPS6223723B2 (enExample)
JPH06172365A (ja) １０−チアイソアロキサジン誘導体およびその用途
Saheb The Synthesis of Fluorinated Thymine Analogues as Potential Anticancer Agents